Provided by Tiger Trade Technology Pte. Ltd.

YD Bio Ltd

4.68
+0.02000.43%
Volume:10K
Turnover:44.36K
Market Cap:330.04M
PE:-40.00
High:4.77
Open:4.75
Low:4.10
Close:4.66
52wk High:25.00
52wk Low:1.70
Shares:70.52M
Float Shares:16.11M
Volume Ratio:0.15
T/O Rate:0.06%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1170
EPS(LYR):-1.2901
ROE:-42.69%
ROA:-25.43%
PB:50.08
PE(LYR):-3.63

Loading ...

YD Bio Reports Peer-Reviewed Nutrients Publication on Omega-3, Vitamins D3 and K2 "heart-Brain-Bone" Axis

Reuters
·
Yesterday

Yd Bio Launches a Physician-Partnership Initiative in Taiwan with the Announcement of Two Nutraceutical Products in Collaboration with the Taiwan Chronic Disease Healthcare Association and the Future Health Institute

THOMSON REUTERS
·
Aug 11

YD Bio Highlights Peer-Reviewed Computational Study Nominating Keratoconus Regenerative Therapy Targets

Reuters
·
Aug 04

YD Bio Launches Cancer Testing Pilot with Numia Health in Canada

Reuters
·
Jul 28

YD Bio Wins Rhode Island, Pennsylvania Lab Licenses, Expanding U.S. Footprint to 46 States

Reuters
·
Jul 02

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 02:48 PM

Reuters
·
Jun 04

Yd Bio Limited Reports Full Year 2025 Financial Results

THOMSON REUTERS
·
May 01

YD Bio FY25 net loss widens to $8.3 million; revenue rises 17% to $596,817

Reuters
·
May 01

YD Bio Ltd trading halted, volatility trading pause

TIPRANKS
·
Apr 08

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 03:56 PM

Reuters
·
Apr 08

YD Bio files Form 3 as director Kochi Chang reports no beneficial ownership

Reuters
·
Apr 02

YD Bio files Form 3; director Jerry Yin-Chia Lee reports no securities owned

Reuters
·
Mar 31

YD Bio files initial beneficial ownership statement; Chief Medical Officer and director Zhang Bo-Xiang reports 31,141 ordinary shares

Reuters
·
Mar 28

YD Bio files initial beneficial ownership statement; CFO Edmund Hen reports no securities beneficially owned

Reuters
·
Mar 27

YD Bio Ltd trading halted, volatility trading pause

TIPRANKS
·
Mar 23

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:43 AM

Reuters
·
Mar 23

YD Bio Limited files Form 3 as CEO Ethan Shen reports 54.34 million ordinary shares owned

Reuters
·
Mar 18

YD Bio details roadmap for integrated oncology ecosystem

TIPRANKS
·
Mar 17

YD Bio outlines plan to integrate cancer detection with dendritic cell immunotherapy by 2027

Reuters
·
Mar 17